New Therapies for the Management of Keloids

Journal of Craniofacial Surgery

Volumn 14, Issue 5, 2003, Pages 654-657

  Poochareon, Varee N ^a   Berman, Brian ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Imiquimod; Interferon; Keloid; Laser therapy

Indexed keywords

ALPHA2B INTERFERON; AMINOQUINOLINE DERIVATIVE; CORTICOSTEROID; IMIQUIMOD; IMMUNOSUPPRESSIVE AGENT; INTERFERON INDUCING AGENT; TACROLIMUS;

ADJUVANT CHEMOTHERAPY; HUMAN; KELOID; LASER SURGERY; REVIEW;

ADRENAL CORTEX HORMONES; AMINOQUINOLINES; CHEMOTHERAPY, ADJUVANT; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON ALFA-2B; INTERFERON INDUCERS; KELOID; LASER SURGERY; TACROLIMUS;

EID: 0642311081     PISSN: 10492275     EISSN: 15363732     Source Type: Journal    
DOI: 10.1097/00001665-200309000-00009     Document Type: Article

References (47)

1. Niessen FB, Spauwen PHM, Schalkwijk J, et al. On the nature of hypertrophic scars and keloids: a review. Plast Reconstr Surg 1999; 104:1435-1458
2. Shaffer JJ, Taylor SC, Cook-Bolden F. Keloidal scars: a review with a critical look at therapeutic options. J Am Acad Dermatol 2002; 46(Suppl):S63
3. Berman B, Kapoor S. Keloid and hypertrophic scar. eMedicine 2001; 2:1-12. Available at: www.emedicine.com
4. Darzi MA, Chowdri NA, Kaul SK, et al. Evaluation of various methods of treating keloids and hypertrophic scars: a 10-year follow-up study. Br J Plast Surg 1992; 45:374-379
5. Berman B, Bieley HC. Adjunct therapies to surgical management of keloids. Dermatol Surg 1996; 22:126-130
6. Lawrence WT. In search of the optimal treatment of keloids: report of a series and a review of the literature. Ann Plast Surg 1991; 27:164-178
7. Berman B, Bieley HC. Keloids. J Am Acad Dermatol 1995; 33:117-123
8. Porter JP. Treatment of the keloid: what is new? Otolarygol Clin North Am 2002; 35:207-220
9. Norris JE. The effect of carbon dioxide laser surgery on the recurrence of keloids. Plast Reconstr Surg 1991; 87:44-49
10. Henderson DL, Cromwell TA, Mes LG. Argon and carbon dioxide laser treatment of hypertrophic and keloid scars. Lasers Surg Med 1984; 3:271-277
11. Apfelberg DB, Maser MR, White DN, et al. Failure of carbon dioxide laser excision of keloids. Lasers Surg Med 1989; 9:382-388
12. Castro DJ, Abergel RP, Meeker CA, et al. Effects of the Nd:YAG laser on DNA synthesis and collagen production in human skin fibroblast cultures. Ann Plast Surg 1983; 11:214-222
13. Kumar K, Kapoor BS, Rai P, et al. In situ irradiation of keloid scars with Nd:YAG laser. J Wound Care 2000; 9:213
14. Alster TS. Improvement of erythematous and hypertrophic scars by the 585 nm flashlamp pulsed dye laser. Ann Plast Surg 1994; 32:186-190
15. Alster TS, Williams CM. Treatment of keloid sternotomy scars with 585 nm flashlamp-pumped pulsed-dye laser. Lancet 1995; 345:1198-2000
16. Connell PG, Harland CC. Treatment of keloid scars with pulsed dye lasers and intralesional steroid. J Cutan Laser Ther 2000; 2:147-150
17. Manuskiatti W, Fitzpatrick RE. Treatment response of keloidal and hypertrophic sternotomy scars: comparison among intralesional corticosteroid, 5-fluorouracil, and 585-nm flashlamp-pumped pulsed-dye laser treatments. Arch Dermatol 2002; 138:1149-1155
18. Berman B, Flores F. Interferons. In: Wolverton SE (ed). Comprehensive Dermatologic Drug Therapy. Philadelphia: WB Saunders, 2001:339-357
19. Berman B, Duncan MR. Short-term keloid treatment in vivo with human interferon alfa-2b results in a selective and persistent normalization of keloidal fibroblast collagen, glycosaminoglycan, and collagenase production in vitro. J Am Acad Dermatol 1989; 21(Part 1):694-702
20. Wong TW, Chiu HC, Yip KM. Intralesional interferon alfa-2b has no effect in the treatment of keloids. Br J Dermatol 1994; 130:683-685
21. Al-Khawajah MM. Failure of interferon alpha-2b in the treatment of mature keloids. Int J Dermatol 1996; 35:515-517
22. Berman B, Flores F. Recurrence rates of excised keloids treated with postoperative triamcinolone, acetonide injections or interferon alfa-2b injections. J Am Acad Dermatol 1997; 37:755-757
23. Conejo-Mir JS, Corbi R. Carbon dioxide laser ablation associated with interferon alfa-2b injections reduces the recurrence of keloids. J Am Acad Dermatol 1998; 39:1039-1040
24. Granstein RD, Rook A, Flotte TJ, et al. A controlled trial of intralesional recombinant interferon-gamma in the treatment of keloidal scarring. Clinical and histologic findings. Arch Dermatol 1990; 126:1295-1302
25. Larrabee Jr, WF, East CA, Jaffe HS, et al. Intralesional interferon gamma treatment of keloids and hypertrophic scars. Arch Otolaryngol Head Neck Surg 1990; 116:1159-1162
26. Sauder D. New immune therapies for skin disease: imiquimod and related compounds. J Cutan Med Surg 2001; 5:2-6
27. Miller RL, Gerster JF, Owens ML, et al. Imiquimod applied topically: a novel immune response modifier and new class of drug. Int J Immunopharmacol 1999; 21:1-14
28. Kaufman J, Berman B. Topical application of imiquimod 5% cream to excision sites is safe and effective in reducing keloid recurrences. J Am Acad Dermatol 2002; 47(Suppl):S209-211
29. Weisberg NK, Varghese M. Therapeutic response of a brother and sister with xeroderma pigmentosum to imiquimod 5% cream. Dermatol Surg 2002; 28:518-523
30. Martinez ML, Sanchez-Carpintero I, North PE, et al. Infantile hemangioma. Arch Dermatol 2002; 138:881-884
31. Barba AR, Kapoor S, Berman B. An open label safety study of topical imiquimod 5% cream in the treatment of molluscum contagiosum in children. Dermatol Online J 2001; 7:20
32. Kim A, Dicarlo J, Cohen C, et al. Are keloids really “gli-1oid”: high-level expression of gli-1 oncogene in keloids. J Am Acad Dermatol 2001; 45:707-711
33. Peacock Jr. EE, Pharmacologic control of surface scarring in human beings. Ann Surg 1981; 193:592-597
34. Dolynchuk KN, Ziesmann M, Serletti JM. Topical putrescine (Fibrostat) in treatment of hypertrophic scars: phase II study. Plast Reconstr Surg 1996; 97:117-123
35. Suzawa H, Kikuchi S, Arai N, et al. The mechanism involved in the inhibitory action of tranilast, an anti-allergic drug, on the release of cytokines on PGE2 from human monocytes-macrophages. Jpn J Pharmacol 1992; 60:85-90
36. Daly TJ, Weston WL. Retinoid effects on fibroblast proliferation and collagen synthesis in vitro and on fibrotic disease in vivo. J Am Acad Dermatol 1986; 15(Part 2):900-902
37. Panabiere-Castaings MN. Retinoic acid in the treatment of keloids. J Dermatol Surg Oncol 1988; 14:1275-1276
38. Bairy KL, Rao CM, Ramesh KV, et al. Effects of antihistamines on wound healing. Indian J Exp Biol 1991; 29:398-399
39. Berman B, Duncan MR. Pentoxifylline inhibits the proliferation of human fibroblasts derived from keloid, scleroderma and morphea skin in their production of collagen, glycosaminoglycans and fibronectin. Br J Dermatol 1990; 123:339-346
40. D'Andrea F, Brongo S, Ferraro G, et al. Prevention and treatment of keloids with intralesional verapamil. Dermatology 2002; 204:60-62
41. Lee RC, Ping JA. Calcium antagonists retard extracellular matrix production in connective tissue equivalent. J Surg Res 1990; 49:463-466
42. Mikulec AA, Hanasono MM, Lum J, et al. Effect of tamoxifen on transforming growth factor beta 1 production by keloid and fetal fibroblasts. Arch Fac Plast Surg 2001; 3:111-114
43. Hu D, Hughes MA, Cherry GW. Topical tamoxifen—a potential therapeutic regimen in treating excessive dermal scarring? Br J Plast Surg 1998; 51:462-469
44. Espana A, Solano T, Quintanilla E. Bleomycin in the treatment of keloids and hypertrophic scars by multiple needle punctures. Dermatol Surg 2001; 27:23-27
45. Uppal RS, Khan U, Kakar S, et al. The effects of a single dose of 5-fluorouracil on keloid scars: a clinical trial of timed wound irrigation after extralesional excision. Plast Reconstr Surg 2001; 108:1218-1224
46. Craft N. Keloids: current concepts in pathogenesis and treatment. Cosmet Dermatol 2002; 15:35-39
47. Mustoe TA, Cooter RD, Gold MH, et al. International clinical recommendations on scar management. Plast Reconstr Surg 2002; 110:560-571